Saturday 17 October 2026 Export ANAB’s income statement to Excel — free account

AnaptysBio, Inc.

AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

46.61 2.10 −4.31%

Follow ANAB

Alert me

Market cap: $1.5B
P/E: 0.0×
Fwd P/E: 220×
Dividend yield: —
F-score: 5/9
Altman Z: 0.84
Beneish M: −2.34
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 9.75

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	6	13	1	2	—	—	—	—	—	—	1

Insider Ownership 2.69%

Capital & Financial Ratios $m

Market Cap 1,460.00

Revenue 232.39

Net Income (26.79)

Free Cash Flow 4.41

Net Debt (286.45)

Current Ratio 7.58

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 220.00

P/S ratio 5.75

P/B ratio 104.91

Past 5Y EPS Growth —

This Y EPS Growth (643.59%)

Next Y EPS Growth 225.44%

Next Y revenue growth (54.95%)

Next 5Y EPS Growth (3.89%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 25.19%

10-year low 10-year high

P/B against its own 10 years 94.63%

10-year low 10-year high

EV/Sales against its own 10 years 47.05%

10-year low 10-year high

EV/FCF against its own 10 years 87.49%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	391	385	312	286
Receivables	7	41	34	26
Inventory	—	—	—	—
Other	—	—	—	—
	407	432	350	316

	2023	2024	2025	Q'26
Payables	5	4	4	8
ST’ Debt	—	—	—	—
Other	—	—	—	—
	37	45	39	42

Compound Annual Growth %

	10y	5y	3y
Sales	29.58%	25.62%	183.58%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(1.28%)	(37.71%)	(47.83%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	26	—	—	—	—
’25	28	22	76	108	235
’24	7	11	30	43	91
’23	1	3	3	9	17
’22	1	1	1	7	10
’21	11	30	21	1	63
’20	15	—	—	60	75

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	—	—	—	—
’25	(11)	(40)	(27)	98	20
’24	(37)	(21)	(10)	(67)	(135)
’23	(25)	(25)	(36)	(34)	(121)
’22	(21)	(24)	(18)	(11)	(74)
’21	(23)	10	(7)	(25)	(46)
’20	(15)	(20)	(17)	38	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	—	—	—	—
’25	(11)	(40)	(27)	98	20
’24	(37)	(21)	(10)	(67)	(136)
’23	(25)	(26)	(37)	(35)	(122)
’22	(21)	(24)	(18)	(11)	(74)
’21	(24)	9	(7)	(25)	(47)
’20	(15)	(20)	(17)	37	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.84)	—	—	—	—
’25	(1.28)	(1.34)	0.52	1.58	(0.46)
’24	(1.64)	(1.71)	(1.14)	(0.72)	(5.12)
’23	(1.58)	(1.50)	(1.41)	(1.59)	(6.08)
’22	(1.31)	(1.15)	(1.18)	(0.93)	(4.57)
’21	(0.66)	(0.02)	(0.24)	(1.18)	(2.11)
’20	(0.30)	(0.79)	(0.87)	1.20	(0.73)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	10.11	36.17	6.67	8.04	11.81	12.13	8.91	8.34	8.14	Analyst estimates 2026–2028 Powerpack
	High	—	68.42	89.33	55.40	20.86	25.26	24.04	20.76	27.54	34.98
People
People	Employees	49	60	78	89	94	102	96	117	136	104
	Revenue/emp, $m	0.34	0.17	0.06	0.09	0.80	0.62	0.11	0.15	0.67	2.26
Income, $m
Income, $m	Revenue	17	10	5	8	75	63	10	17	91	235
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(4)	(30)	(62)	(97)	(20)	(58)	(129)	(164)	(145)	(13)
	EBT margin, %	(25.53)	(300.70)	(1,236.96)	(1,218.60)	(26.57)	(91.49)	(1,251.09)	(953.68)	(159.10)	(5.57)
	Net income	(4)	(30)	(62)	(97)	(20)	(58)	(129)	(164)	(145)	(13)
	Depreciation	0	0	(1)	(1)	2	3	0	(8)	(8)	(2)
Per share, $
Per share, $	Revenue	6.33	0.51	0.20	0.30	2.75	2.30	0.37	0.64	3.22	8.16
	Earnings	(1.62)	(1.52)	(2.50)	(3.60)	(0.73)	(2.11)	(4.57)	(6.08)	(5.12)	(0.46)
	Cash flow	(3.42)	(0.98)	(1.97)	(2.57)	(0.52)	(1.67)	(2.61)	(4.49)	(4.77)	0.68
	Capex	(0.02)	(0.01)	(0.04)	(0.03)	(0.02)	(0.05)	(0.01)	(0.03)	(0.01)	0.00
	Free cash flow	(3.44)	(1.00)	(2.01)	(2.60)	(0.54)	(1.72)	(2.63)	(4.52)	(4.78)	0.68
	Book value	14.89	15.55	19.71	14.97	14.53	12.99	9.31	3.27	2.50	1.29
	Shares, m	3	20	25	27	27	27	28	27	28	29
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	1.79	83.01	59.07	18.32	4.71	10.06	53.33	22.71	2.75	3.96
	P/B	0.00	4.31	2.16	0.72	0.99	1.78	2.09	4.42	3.54	24.98
	EV/Sales	(0.45)	67.94	35.16	(4.92)	0.00	1.42	10.68	0.06	(1.45)	2.64
	EV/FCF	0.83	(55.02)	(12.60)	1.12	0.00	(1.90)	(1.49)	(0.01)	0.98	31.63
Cash, $m
Cash, $m	Operating cash flow	(9)	(19)	(49)	(70)	(14)	(46)	(74)	(121)	(135)	20
	Capex	0	0	(1)	(1)	(1)	(1)	0	(1)	0	0
	Free cash flow	(9)	(20)	(50)	(70)	(15)	(47)	(74)	(122)	(136)	20
Balance, $m
Balance, $m	Working capital	53	239	412	348	377	538	421	369	386	312
	Total debt	14	8	1	1	0	19	322	—	—	—
	Net debt	(37)	(241)	(427)	(374)	(394)	(548)	(441)	(391)	(385)	(312)
	Shareholders’ equity	39	308	486	405	397	356	262	88	71	37
Returns, %
Returns, %	ROA	(7.19)	(15.36)	(14.71)	(20.62)	(4.68)	(10.91)	(20.54)	(30.79)	(31.02)	(3.12)
	ROIC	(102.47)	(26.96)	(70.34)	(218.14)	(484.87)	0.00	0.00	0.00	0.00	0.00
	ROE	11.60	(22.33)	(15.53)	(21.84)	(4.97)	(15.35)	(41.62)	(93.44)	(182.71)	(24.49)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)	Compare
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%	Compare
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
IMCR Immunocore Holdings PLC Sponsored ADR	$1.5B	— (loss-making)	208×	+18.34% (above 0%: growing)	n/m	−40.74% (below 0%: shrinking)	99.06%	(2.58%)	Compare
RARE Ultragenyx Pharmaceutical Inc.	$1.5B	— (loss-making)	— (loss-making)	+28.14% (above 0%: growing)	n/m	+12.50% (above 0%: growing)	84.11%	(35.05%)	Compare
ANAB AnaptysBio, Inc.	$1.5B	— (loss-making)	220×	−7.98% (below 0%: shrinking)	n/m	−141.60% (below 0%: shrinking)	100.00%	(135.53%)
RAPP Rapport Therapeutics, Inc.	$1.4B	— (loss-making)	—	—	n/m	−64.75% (below 0%: shrinking)	100.00%	0.00%	Compare
AAPG Ascentage Pharma Group International - Unsponsored ADR	$1.4B	—	—	—	—	+17.74% (above 0%: growing)	—	—	Compare
Median of peers	$1.5B	—	—	+11.00%	—	−14.12%	100.00%	(2.58%)

All 614 Biotechnology stocks →

AnaptysBio, Inc. (ANAB) key facts

Strength: AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024.
AnaptysBio, Inc. (ANAB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ANAB traded at $46.61, a market capitalization of $1.5 billion.
Return on equity was −24.5% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.84 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.